[go: up one dir, main page]

ECSP10010694A - DERIVADOS DE BENZOXAZINONA QUE ACTÚAN COMO AGONISTAS DE RECEPTORES ADRENÉRGICOS ß2 PARA EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS - Google Patents

DERIVADOS DE BENZOXAZINONA QUE ACTÚAN COMO AGONISTAS DE RECEPTORES ADRENÉRGICOS ß2 PARA EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS

Info

Publication number
ECSP10010694A
ECSP10010694A EC2010010694A ECSP10010694A ECSP10010694A EC SP10010694 A ECSP10010694 A EC SP10010694A EC 2010010694 A EC2010010694 A EC 2010010694A EC SP10010694 A ECSP10010694 A EC SP10010694A EC SP10010694 A ECSP10010694 A EC SP10010694A
Authority
EC
Ecuador
Prior art keywords
treatment
respiratory disorders
derivatives acting
benzoxazinone derivatives
adrenergic
Prior art date
Application number
EC2010010694A
Other languages
English (en)
Inventor
Richard R Evans
Roger Bonnert
Stephen Connolly
Anthony Ronald Cook
Piotr Raubo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010694A publication Critical patent/ECSP10010694A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I), en el que W, R1, R2 y R3 son como se definen en la descripción, procesos para su preparación, composiciones farmacéuticas que lo contienen y su uso en terapia.
EC2010010694A 2008-06-18 2010-12-17 DERIVADOS DE BENZOXAZINONA QUE ACTÚAN COMO AGONISTAS DE RECEPTORES ADRENÉRGICOS ß2 PARA EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS ECSP10010694A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7342008P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
ECSP10010694A true ECSP10010694A (es) 2011-01-31

Family

ID=41434296

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010694A ECSP10010694A (es) 2008-06-18 2010-12-17 DERIVADOS DE BENZOXAZINONA QUE ACTÚAN COMO AGONISTAS DE RECEPTORES ADRENÉRGICOS ß2 PARA EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS

Country Status (21)

Country Link
US (1) US8017602B2 (es)
EP (1) EP2303873A4 (es)
JP (1) JP2011524896A (es)
KR (1) KR20110017456A (es)
CN (1) CN102124003A (es)
AR (1) AR072189A1 (es)
AU (1) AU2009260899B2 (es)
BR (1) BRPI0915428A2 (es)
CA (1) CA2726746A1 (es)
CL (1) CL2010001459A1 (es)
CO (1) CO6321269A2 (es)
CR (1) CR11856A (es)
DO (1) DOP2010000389A (es)
EA (1) EA201001747A1 (es)
EC (1) ECSP10010694A (es)
IL (1) IL209731A0 (es)
MX (1) MX2010013477A (es)
TW (1) TW201002696A (es)
UY (1) UY31905A (es)
WO (1) WO2009154557A1 (es)
ZA (1) ZA201008886B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102124003A (zh) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 作为治疗呼吸系统疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
CN102993116A (zh) * 2012-12-04 2013-03-27 常州大学 一种苯并噁嗪类激动剂的制备方法
EA029518B1 (ru) * 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
CN104496920A (zh) * 2014-12-04 2015-04-08 北京理工大学 一种n-烯丙基-二取代四唑及其制备方法和检测方法
CN107188865B (zh) * 2016-03-14 2019-08-27 益方生物科技（上海）有限公司 苯并噁嗪化合物及其制备方法和用途
PL424609A1 (pl) * 2018-02-16 2019-08-26 Uniwersytet Przyrodniczy we Wrocławiu Zastosowanie 6-(tert-butylo)-3-dodecylo-3,4-dihydro-2H-benzo[e][1,3]oxazyny
CN110028521B (zh) * 2019-05-27 2020-07-14 湖南科技大学 11-芳基-1,4-苯并恶嗪酮并咪唑啉类化合物及其制备方法和用途
EP4194453A1 (en) 2021-12-08 2023-06-14 Basf Se Pyrazine compounds for the control of invertebrate pests
WO2023104564A1 (en) 2021-12-08 2023-06-15 Basf Se Pyrazine compounds for the control of invertebrate pests
CN117143019B (zh) * 2023-07-28 2025-11-25 常州大学 用作β2-肾上腺素受体别构拮抗剂的吡唑酰胺类衍生物

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653977A (en) 1953-09-29 Chxnx
US3775477A (en) 1971-03-10 1973-11-27 Sterling Drug Inc N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DK173685A (da) 1984-04-17 1985-10-18 Glaxo Group Ltd Ethanolaminderivater
US4554287A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones
US4554284A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8525483D0 (en) 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
GB8718938D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
AU629989B2 (en) 1989-10-10 1992-10-15 Glaxo Group Limited Phenethanolamine derivatives
IE914003A1 (en) 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
GB9211172D0 (en) 1992-05-27 1992-07-08 Fisons Plc Compounds
GB9210632D0 (en) 1992-05-19 1992-07-01 Fisons Plc Compounds
US5648370A (en) 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
TW356468B (en) 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
GB9526511D0 (en) 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
JP4176148B2 (ja) 1996-05-20 2008-11-05 帝人ファーマ株式会社 ジアリールアルキル環状ジアミン誘導体およびその治療薬としての使用
SE9700706D0 (sv) 1997-02-27 1997-02-27 Astra Pharma Prod Process for the preparation of benzothiazoline compounds
SE9701304D0 (sv) 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
SE9902938D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902937D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902936D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
ATE417606T1 (de) 2001-09-14 2009-01-15 Glaxo Group Ltd Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
CA2565243A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
WO2005121065A2 (en) 2004-06-03 2005-12-22 Theravance, Inc. DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
US7566785B2 (en) 2004-09-10 2009-07-28 Theravance, Inc. Amidine substituted aryl aniline compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
AU2006271356A1 (en) 2005-07-18 2007-01-25 Pfizer Limited Process for the preparation of sulfonamide derivatives
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) * 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
WO2008041914A1 (en) 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JP2010513439A (ja) 2006-12-20 2010-04-30 アストラゼネカ・アクチエボラーグ アミン誘導体およびｂ２アドレナリン受容体活性の調節におけるその使用
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
CN102124003A (zh) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 作为治疗呼吸系统疾病的β2肾上腺素受体拮抗剂的苯并噁嗪酮衍生物
UY31920A (es) 2008-06-20 2010-01-29 Astrazeneca Ab Nueva combinacion-408

Also Published As

Publication number Publication date
EP2303873A4 (en) 2012-01-04
MX2010013477A (es) 2010-12-21
AU2009260899A1 (en) 2009-12-23
CL2010001459A1 (es) 2011-09-23
CR11856A (es) 2011-02-25
KR20110017456A (ko) 2011-02-21
TW201002696A (en) 2010-01-16
EA201001747A1 (ru) 2011-08-30
WO2009154557A1 (en) 2009-12-23
JP2011524896A (ja) 2011-09-08
CO6321269A2 (es) 2011-09-20
US20100105642A1 (en) 2010-04-29
DOP2010000389A (es) 2011-01-15
AU2009260899B2 (en) 2012-02-23
CA2726746A1 (en) 2009-12-23
BRPI0915428A2 (pt) 2015-11-03
CN102124003A (zh) 2011-07-13
AR072189A1 (es) 2010-08-11
EP2303873A1 (en) 2011-04-06
UY31905A (es) 2010-01-29
ZA201008886B (en) 2011-08-31
US8017602B2 (en) 2011-09-13
IL209731A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
ECSP10010694A (es) DERIVADOS DE BENZOXAZINONA QUE ACTÚAN COMO AGONISTAS DE RECEPTORES ADRENÉRGICOS ß2 PARA EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
HN2010002030A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR11861A (es) Compuestos organicos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
UY30206A1 (es) Derivados de diamina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
UY31700A (es) Tiazolil-dihidro-indazoles
CL2011002946A1 (es) Compuestos derivados de tiazoltiadiazol aminopirazol, inhibidores de proteina quinasa c-met; composicion farmaceutica que los comprende y su uso en el tratamiento de diferentes tipos de cancer.
CO6382113A2 (es) Compuestos quimicos